Bayer Healthcare, LLC v. United States Food and Drug Administration
942 F. Supp. 2d 17
D.D.C.2013Background
- Bayer owns Baytril 100, a bovine BRD drug with a multi-day label and a single-dose advantage; the 444 patent expired 2006, the 506 patent expires 2015.
- Bayer filed a 2006 Citizen Petition asking FDA not to approve a Baytril generic limited to multi-day dosing due to off-label single-dose risk; Bayer supported it with market research and veterinarian affidavits.
- FDA did not respond to Bayer’s Citizen Petition before approving Norbrook’s ANADA for Enroflox 100 in 2013, despite acknowledging a tentative response was contemplated.
- Norbrook received FDA approval on March 29, 2013 for Enroflox 100 for single-dose (swine) or multi-day cattle therapy; its labeling mirrors Baytril’s multi-day dosing and warns against extra-label use.
- Bayer filed this APA challenge and TRO motion, arguing FDA failed to consider the Petition and acted arbitrarily; the Court granted TRO suspending Enroflox 100 labeling for cattle.
- The Court’s order and related proceedings led to this memorandum outlining why Bayer is likely to succeed, would suffer irreparable harm, and public and equity interests support relief.
Issues
| Issue | Plaintiff's Argument | Defendant's Argument | Held |
|---|---|---|---|
| Whether FDA acted arbitrarily and capriciously in approving Norbrook’s ANADA | Bayer contends FDA ignored the Petition and failed to provide reasoned decisionmaking | FDA claims decision was reasonable based on record and expertise | Yes; likely to prevail on merits; FDA failed to consider the Petition and provide rational basis |
| Whether Bayer suffers irreparable harm without TRO | Enroflox entry will erode Bayer’s market share and funds irreparably | Harm alleged is monetary and not irreparable; harms can be compensated | Yes; Bayer would face irreparable harm absent relief |
| Whether the balance of equities supports continued TRO | FDA’s delay harms Bayer; Norbrook harmed by delay but relief favors public | FDA and Norbrook have substantial interests in upholding approval | Yes; Bayer’s harm outweighs other parties’ interests at this stage |
| Whether public interest favors enforcing statutory compliance | Statutory mandate requires considering labeling use in practice | Public interest in agency efficiency and expertise | Yes; public interest supports compliance with governing statute |
Key Cases Cited
- Winter v. NRDC, 555 U.S. 7 (U.S. 2008) (injunctions require four-factor showing; not just possible harm)
- Motor Vehicle Mfrs. Ass’n v. State Farm, 463 U.S. 29 (U.S. 1983) (arbitrary and capricious review; narrow scope of review)
- Bowen v. American Hosp. Ass’n, 476 U.S. 610 (U.S. 1986) (require rational connection between facts and decision)
- Overton Park v. Volpe, 401 U.S. 402 (U.S. 1971) (presumption of regularity but must consider relevant data)
- Citizens to Preserve Overton Park v. Volpe, 401 U.S. 402 (U.S. 1971) (precedent for agency action review standards)
- Davis v. Pension Benefit Guar. Corp., 571 F.3d 1288 (D.C. Cir. 2009) (sliding scale only applies with four-factor test; must weigh factors)